Kock H J, Krause U, Pietsch M, Rasfeld S, Walz M K
Abteilung für Allgemeine Chirurgie, Chirurgische Klinik und Poliklinik, Universität Essen.
Dtsch Med Wochenschr. 1996 Jan 19;121(3):47-51. doi: 10.1055/s-2008-1042970.
To assess retrospectively duration of functioning and rate of complications of a totally implantable venous access system used for long-term chemotherapy.
Between 1985 and 1993, a central venous access system (Port-a-Cath) had been implanted subcutaneously for long-term chemotherapy in 1000 patients (479 males, 521 females; mean age 49 [15-86] years). Follow-up observations lasted until the end of the chemotherapy or the removal of the system.
Mean time of functioning of the catheter system was 284 (2-1563) days. The complication rate was 12.8%: catheter infection in 4.9% and catheter thrombosis in 3.2%. A further 4.7% of patients had less common complications (malfunction, catheter dislocation, skin necrosis, catheter break or disconnection, pneumothorax). A total of 119 (11.9%) systems had to be removed because of complications. The rates of infection and of other complications were significantly lower in patients with solid tumours (2 and 4%, respectively) than in those with haematological disease (6 and 8%) (P < 0.05 for each).
Totally implantable venous access systems are suitable for long-term chemotherapy and cause few complications.
回顾性评估用于长期化疗的全植入式静脉通路系统的使用期限及并发症发生率。
1985年至1993年间，1000例患者（男479例，女521例；平均年龄49[15 - 86]岁）皮下植入中心静脉通路系统（植入式静脉输液港）用于长期化疗。随访观察持续至化疗结束或系统移除。
导管系统的平均使用时间为284（2 - 1563）天。并发症发生率为12.8%：导管感染占4.9%，导管血栓形成占3.2%。另外4.7%的患者出现较少见的并发症（功能障碍、导管移位、皮肤坏死、导管断裂或脱节、气胸）。共有119（11.9%）个系统因并发症而不得不移除。实体瘤患者的感染率和其他并发症发生率（分别为2%和4%）显著低于血液系统疾病患者（分别为6%和8%）（每项P < 0.05）。
全植入式静脉通路系统适用于长期化疗，且并发症较少。
